Pharmacist Checklist
Guidance for dispensing Neotigason (acitretin)

Neotigason belongs to the retinoid class of drugs that cause severe birth defects. Foetal exposure to Neotigason, even for short periods of time, presents a high risk of severe and serious congenital malformations and an increased risk of spontaneous abortion.

Neotigason is therefore strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions of the Neotigason Pregnancy Prevention Programme are met.

If you are aware that a pregnancy has occurred in a woman treated with Neotigason, treatment should be stopped immediately and the woman should be promptly referred to the prescribing doctor.

If you are aware that a female patient has become pregnant within 3 years of stopping Neotigason she should be referred to her prescribing doctor.

Patient Reminder Card: Counsel all patients (male and female) on the patient reminder card which is included in the product packaging. In the event that broken bulk dispensing cannot be avoided, the patient should be provided with a copy of the package leaflet and patient reminder card.

As a pharmacist, you should only dispense Neotigason after checking the following information:

For women of child-bearing potential:	**Pharmacist confirm [Yes/No]**
• In order to support regular follow up, including pregnancy testing and monitoring, the prescription for Neotigason should be limited to a 30-day supply.	YES ☐ NO ☐
All patients should be instructed:	
• Never to give Neotigason to another person.	YES ☐ NO ☐
• To return any unused capsules to their pharmacist at the end of treatment.	YES ☐ NO ☐
• Not to donate blood during Neotigason therapy and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient.	YES ☐ NO ☐

Reporting suspected adverse events or reactions

Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems to allow continued monitoring of the benefit-risk balance of the medicinal product.

PBS Information: Authority Required (STREAMLINED). Refer to PBS for full authority information.

Before dispensing please review the full product information by scanning the QR code.

Teva Pharma Australia Pty Limited
Level 1, 37 Epping Rd, Macquarie Park, NSW, 2113
1800 288 382 | **www.tevapharma.com.au**

NEOT-AU-NP-00011
Date of Preparation: Mar 2025 | Date of Expiration: Mar 2027